Dr Jinge Si is considered a leader in the field of Gynecology and Obstetrics in China. She has a medical degree from China Medical University and was awarded a Ph.D. by Southern Medical University in China, back in 2017.

She is currently the leader of 2 projects in OB/GYN right now, both of which are funded by government grants.

One project is specifically in regards to ovarian cancer.

As you may know, Ovarian cancer is the most lethal gynecological cancer affecting women in Australia. The 5-year survival rate for ovarian cancer is 45.7%.

There is no early detection test for ovarian cancer. Only 29% of women diagnosed at a late stage can survive for more than five years. These factors urge scientists to find a way to detect it in its early stages.

Her project “endometrial originated microRNA-200c targeting LPA in ovarian cancer” is focused on early detection, angiogenesis, signaling pathways and targeted therapies strategies.

Her discovery of micro-RNAs (miRNA)-200c, a small noncoding RNA molecule targeting multiple mRNAs and regulation of gene expression, has revealed the existence of a new array for regulation of genes involved in ovarian cancer.

Most of her innovative approaches already demonstrate promising activity in ovarian cancer and have the potential to improve the early detection and outcome in women with ovarian cancer.

Her other project “MIRNA-21 regulates immune tolerance by SATB1 on PD-1/PD-L1 in pathogenesis of pre-eclampsia”. it is rarely explored in Australia previously.

Pre-eclampsia (PE) is a complication of pregnancy that is associated with substantial maternal and fetal morbidity and mortality.

The disease presents with new-onset hypertension and often proteinuria in the mother, which can progress to multi-organ dysfunction. Preeclampsia (PE) continues to represent a worldwide problem and challenge for both clinicians and laboratory-based doctors.

The knowledge acquired regarding its pathogenesis and pathophysiology is limited. Her study highlights that overexpression of miR-21 is involved in PE by regulating immune tolerance, which may provide a new idea for further study of the pathogenesis of PE.

Under her research, miRNAs will become a potential therapeutic target and a diagnostic tool in PE. There is in lack of related research in Australia in this field, her innovative approach may be a step towards finding relevant biomarkers for complicated pregnancy which is of great value for the Australian people.